Yuan Wu, Yu Jiang, Bin Xiao, Lijun Xie, Nanjiang Zhou, Aoguo Zeng, Cuizhong Liu
{"title":"TFR1作为COPD患者肺纤维化发展的生物标志物","authors":"Yuan Wu, Yu Jiang, Bin Xiao, Lijun Xie, Nanjiang Zhou, Aoguo Zeng, Cuizhong Liu","doi":"10.2147/COPD.S527782","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis is involved in chronic lung injury, including COPD and pulmonary fibrosis. In this study, we investigated the role of transferrin protein 1 (TFR1), as a ferroptosis marker, in the development of COPD-associated pulmonary fibrosis.</p><p><strong>Methods: </strong>The expression of TFR1 was elevated in 97 patients with COPD. The correlation analysis of the clinical characteristic was performed including the frequency of acute exacerbation, the fibrosis score, etc. and the expression of TFR1. Animal experiments were carried out to verify TFR1 expression in a rat COPD model.</p><p><strong>Results: </strong>The results showed that the expression of TFR1 was related to DLCO%, 6 MWT, GOLD grade, frequency of acute exacerbation and fibrosis score. Together, in the rat COPD model, higher TFR1 was related to a higher lung injury score and a higher lung fibrosis score.</p><p><strong>Conclusion: </strong>In summary, these results indicated that serum TFR1 levels related to the severity of pulmonary fibrosis in clinical practice and may provide a potential target for the treatment of pulmonary fibrosis development from patients with COPD in the future.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2715-2725"},"PeriodicalIF":3.1000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335247/pdf/","citationCount":"0","resultStr":"{\"title\":\"TFR1 as a Biomarker of Pulmonary Fibrosis Development in COPD Patients.\",\"authors\":\"Yuan Wu, Yu Jiang, Bin Xiao, Lijun Xie, Nanjiang Zhou, Aoguo Zeng, Cuizhong Liu\",\"doi\":\"10.2147/COPD.S527782\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Ferroptosis is involved in chronic lung injury, including COPD and pulmonary fibrosis. In this study, we investigated the role of transferrin protein 1 (TFR1), as a ferroptosis marker, in the development of COPD-associated pulmonary fibrosis.</p><p><strong>Methods: </strong>The expression of TFR1 was elevated in 97 patients with COPD. The correlation analysis of the clinical characteristic was performed including the frequency of acute exacerbation, the fibrosis score, etc. and the expression of TFR1. Animal experiments were carried out to verify TFR1 expression in a rat COPD model.</p><p><strong>Results: </strong>The results showed that the expression of TFR1 was related to DLCO%, 6 MWT, GOLD grade, frequency of acute exacerbation and fibrosis score. Together, in the rat COPD model, higher TFR1 was related to a higher lung injury score and a higher lung fibrosis score.</p><p><strong>Conclusion: </strong>In summary, these results indicated that serum TFR1 levels related to the severity of pulmonary fibrosis in clinical practice and may provide a potential target for the treatment of pulmonary fibrosis development from patients with COPD in the future.</p>\",\"PeriodicalId\":48818,\"journal\":{\"name\":\"International Journal of Chronic Obstructive Pulmonary Disease\",\"volume\":\"20 \",\"pages\":\"2715-2725\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335247/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Chronic Obstructive Pulmonary Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/COPD.S527782\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/COPD.S527782","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
TFR1 as a Biomarker of Pulmonary Fibrosis Development in COPD Patients.
Background: Ferroptosis is involved in chronic lung injury, including COPD and pulmonary fibrosis. In this study, we investigated the role of transferrin protein 1 (TFR1), as a ferroptosis marker, in the development of COPD-associated pulmonary fibrosis.
Methods: The expression of TFR1 was elevated in 97 patients with COPD. The correlation analysis of the clinical characteristic was performed including the frequency of acute exacerbation, the fibrosis score, etc. and the expression of TFR1. Animal experiments were carried out to verify TFR1 expression in a rat COPD model.
Results: The results showed that the expression of TFR1 was related to DLCO%, 6 MWT, GOLD grade, frequency of acute exacerbation and fibrosis score. Together, in the rat COPD model, higher TFR1 was related to a higher lung injury score and a higher lung fibrosis score.
Conclusion: In summary, these results indicated that serum TFR1 levels related to the severity of pulmonary fibrosis in clinical practice and may provide a potential target for the treatment of pulmonary fibrosis development from patients with COPD in the future.
期刊介绍：
An international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
